Home › Research › Biomarkers
Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006
Bryan Dirks, Samantha Friend, Becky Howell, Christine M Murphy, Peter M Zhang, Xiaoshu Feng, Sanjeev S Pathak. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In Part 1 (currently ongoing), between February 6, 2024, and December 27, 2024, 322 adults were screened, of whom 75 (aged 59-89 years) met NIA-AA and IPA criteria. Of these, 23 met clinical criteria for ADP but were not positive for APS or APS2, despite meeting historical biomarker requirements. We will present detailed biomarker results on the population, including apolipoprotein E (apoE) proteotype, Aβ42/40 ratio, and p-tau217 ratio. Clinical presentation and related information will be detailed as well. Biomarkers, rather than syndromic presentation, are recommended as a mechanism by which to define AD biologically. Since biomarker data from patients presenting with clinical symptoms consistent with Alzheimer's disease dementia and psychosis are sparse, we present biomarker data in a rigorously phenotyped population. These results can also inform the design and execution of clinical trials in ADP in the future.
What this study adds
Evidence grade: Low
This is a trial of 322 participants. This ongoing study presents plasma biomarker data in people with Alzheimer's disease psychosis, and notes that 23 participants met clinical criteria for the condition but were not positive on amyloid tests. The results are intended to inform future clinical trial design, not to treat or prevent the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dirks, B., Friend, S., Howell, B., Murphy, C. M., Zhang, P. M., Feng, X., et al. (2025). Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_106556
Vancouver
Dirks B, Friend S, Howell B, Murphy CM, Zhang PM, Feng X, et al. Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_106556. PMID: 41451623.
BibTeX
@article{dirks2025-41451623,
author = {Dirks, Bryan and Friend, Samantha and Howell, Becky and Murphy, Christine M and Zhang, Peter M and Feng, Xiaoshu and Pathak, Sanjeev S},
title = {{Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70859_106556},
pmid = {41451623},
url = {https://doi.org/10.1002/alz70859_106556}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- In Part 1 (currently ongoing), between February 6, 2024, and December 27, 2024, 322 adults were screened, of whom 75 (aged 59-89 years) met NIA-AA and IPA criteria.
- Of these, 23 met clinical criteria for ADP but were not positive for APS or APS2, despite meeting historical biomarker requirements.
- We will present detailed biomarker results on the population, including apolipoprotein E (apoE) proteotype, Aβ42/40 ratio, and p-tau217 ratio.
- Clinical presentation and related information will be detailed as well.
- Biomarkers, rather than syndromic presentation, are recommended as a mechanism by which to define AD biologically.
Why it matters
This ongoing study presents plasma biomarker data in people with Alzheimer's disease psychosis, and notes that 23 participants met clinical criteria for the condition but were not positive on amyloid tests. The results are intended to inform future clinical trial design, not to treat or prevent the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designclinical trial
- Participants322
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 322 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Sanjeev S Pathak: h-index 3 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Acadia Pharmaceuticals (United States): institution h-index 94 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41451623) |
| Free to read | 2 / 2 | Free to read |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70859_106556
- PubMed: 41451623
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.